InsiderTrades.com logo
Bill Gates’ is about to mint millionaires (again) with Stargate.
From Brownstone Research   |   Ad
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
Click here and I’ll tell you everything you need to know.

CYCC Insider Trading

Insider Ownership Percentage: 8.00%
Insider Buying (Last 12 Months): $26,334.36
Insider Selling (Last 12 Months): $0.00

Cyclacel Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Cyclacel Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclacel Pharmaceuticals Share Price & Price History

Current Price: $0.37
Price Change: ▼ Price Decrease of -0.0031 (-0.83%)
As of 11/18/2024 01:00 PM ET

This chart shows the closing price history over time for CYCC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Bill Gates’ is about to mint millionaires (again) with Stargate.
From Brownstone Research   |   Ad
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
Click here and I’ll tell you everything you need to know.

Cyclacel Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/21/2023Paul McbarronInsiderBuy1,886$3.31$6,242.6633,378View SEC Filing Icon  
12/21/2023Spiro George RombotisCEOBuy6,070$3.31$20,091.7068,658View SEC Filing Icon  
11/30/2021Sam L. BarkerDirectorSell0$53.55$0.00View SEC Filing Icon  
11/18/2021Spiro George RombotisCEOBuy266$67.50$17,955.00View SEC Filing Icon  
See Full Table
FREE investing Class TOMORROW + 2 FREE Bonuses
From Unstoppable Prosperity   |   Ad
Over the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stocks that outperform the market. It helps me understand which stocks are worth investing in now…AND which ones you should avoid at all costs! Tomorrow, during my LIVE intro to investing class online, my team will show you how exactly how it works
[YES, I'D LIKE TO REGISTER FOR CHARLES PAYNE'S UPCOMING INTRO TO INVESTING CLASS NOW!]

SEC Filings (Institutional Ownership Changes) for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

23.58% of Cyclacel Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CYCC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Cyclacel Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2024Armistice Capital LLC134,000$0.22M0.0%N/A9.178%Search for SEC Filing on Google Icon
5/10/2024Acadian Asset Management LLC14,285$29K0.0%-41.0%1.084%Search for SEC Filing on Google Icon
11/1/2022Kestra Advisory Services LLC23,000$34K0.0%N/A0.183%Search for SEC Filing on Google Icon
10/25/2022Raymond James Financial Services Advisors Inc.20,806$30K0.0%-32.5%0.166%Search for SEC Filing on Google Icon
10/18/2022McIlrath & Eck LLC26,342$38K0.0%N/A0.210%Search for SEC Filing on Google Icon
8/15/2022Sio Capital Management LLC454,355$0.49M0.2%+7.5%4.546%Search for SEC Filing on Google Icon
2/10/2022Acadian Asset Management LLC23,242$89K0.0%N/A0.233%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Advisers LP121,500$0.64M0.0%+929.7%1.316%Search for SEC Filing on Google Icon
11/15/2021Pura Vida Investments LLC105,141$0.55M0.0%-33.2%1.139%Search for SEC Filing on Google Icon
11/15/2021Tri Locum Partners LP522,943$2.76M1.1%+66.9%5.663%Search for SEC Filing on Google Icon
11/12/2021Affinity Asset Advisors LLC400,000$2.11M0.5%+5.3%4.332%Search for SEC Filing on Google Icon
11/2/2021Raymond James Financial Services Advisors Inc.10,006$53K0.0%-83.3%0.108%Search for SEC Filing on Google Icon
10/15/2021NEXT Financial Group Inc14,752$77K0.0%+70.0%0.160%Search for SEC Filing on Google Icon
8/18/2021Ikarian Capital LLC100,000$0.59M0.0%-66.7%1.083%Search for SEC Filing on Google Icon
8/17/2021Boothbay Fund Management LLC10,545$62K0.0%-66.7%0.114%Search for SEC Filing on Google Icon
8/17/2021Citadel Advisors LLC250,797$1.49M0.0%-14.7%2.716%Search for SEC Filing on Google Icon
8/16/2021Tri Locum Partners LP313,331$1.86M0.6%+6.8%3.393%Search for SEC Filing on Google Icon
8/16/2021Schonfeld Strategic Advisors LLC102,525$0.61M0.0%-25.0%1.110%Search for SEC Filing on Google Icon
8/16/2021Maven Securities LTD234,500$1.43M0.1%-6.2%2.540%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp14,957$89K0.0%N/A0.162%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC50,860$0.30M0.0%+143.3%0.551%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.327,658$1.94M0.0%+9.2%3.548%Search for SEC Filing on Google Icon
7/31/2021NEXT Financial Group Inc8,680$51K0.0%N/A0.094%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC13,108$93K0.0%+27.3%0.142%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC23,836$0.17M0.0%N/A0.258%Search for SEC Filing on Google Icon
5/18/2021Point72 Asset Management L.P.230,000$1.64M0.0%N/A2.491%Search for SEC Filing on Google Icon
5/18/2021Verition Fund Management LLC116,674$0.83M0.0%N/A1.264%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley100,000$0.71M0.0%-13.0%1.083%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC293,867$2.09M0.0%N/A3.182%Search for SEC Filing on Google Icon
5/18/2021Silverarc Capital Management LLC250,000$1.78M1.0%N/A2.707%Search for SEC Filing on Google Icon
5/17/2021Schonfeld Strategic Advisors LLC136,725$0.97M0.0%N/A1.481%Search for SEC Filing on Google Icon
5/17/2021Sphera Funds Management LTD.508,322$3.61M0.3%N/A5.505%Search for SEC Filing on Google Icon
5/17/2021Ikarian Capital LLC300,000$2.13M0.1%-23.4%3.249%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC20,904$0.15M0.0%N/A0.226%Search for SEC Filing on Google Icon
5/12/2021Pura Vida Investments LLC273,958$1.95M0.1%-42.3%2.967%Search for SEC Filing on Google Icon
5/11/2021Acadian Asset Management LLC34,057$0.24M0.0%N/A0.369%Search for SEC Filing on Google Icon
4/12/2021Valeo Financial Advisors LLC4,500$32K0.0%N/A0.063%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC10,293$80K0.0%N/A0.212%Search for SEC Filing on Google Icon
2/16/2021Pura Vida Investments LLC475,000$3.71M0.1%N/A9.766%Search for SEC Filing on Google Icon
2/16/2021Acuta Capital Partners LLC150,000$1.17M0.3%N/A3.084%Search for SEC Filing on Google Icon
2/12/2021Raymond James Financial Services Advisors Inc.57,006$0.45M0.0%+24.6%1.172%Search for SEC Filing on Google Icon
2/12/2021Ikarian Capital LLC391,450$3.06M0.1%N/A8.048%Search for SEC Filing on Google Icon
11/4/2020Raymond James Financial Services Advisors Inc.45,756$0.17M0.0%+48.8%0.941%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Read More on Cyclacel Pharmaceuticals

Today's Range

Now: $0.37
Low: $0.36
High: $0.37

50 Day Range

MA: $0.85
Low: $0.37
High: $1.43

52 Week Range

Now: $0.37
Low: $0.35
High: $6.00

Volume

134,821 shs

Average Volume

709,631 shs

Market Capitalization

$797,435.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Who are the company insiders with the largest holdings of Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' top insider investors include:
  1. Spiro George Rombotis (CEO)
  2. Paul Mcbarron (Insider)
Learn More about top insider investors at Cyclacel Pharmaceuticals.
Bill Gates’ is about to mint millionaires (again) with Stargate.
From Brownstone Research   |   Ad
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
Click here and I’ll tell you everything you need to know.